GlassScriptPhysician profile
Masha Nakelchik
NPI 1255346623
$23,721.62
in general payments reported to CMS, 2019-2025
77 companies · $4,347 in 2025
The $4,347 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,221 · 2020: $2,158 · 2021: $3,098 · 2022: $3,485 · 2023: $4,231 · 2024: $4,181 · 2025: $4,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,746.92 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,232.08 | 2019-2025 | |
| Novo Nordisk INC | $1,864.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,817.79 | 2019-2025 | |
| Amgen INC. | $1,371.90 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $1,349.51 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $1,218.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,216.67 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,028.92 | 2022-2025 | Caplyta |
| Mylan Specialty L.P. | $762.00 | 2019-2024 | Yupelri |
| Astellas Pharma US INC | $650.23 | 2020-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $638.38 | 2019-2021 | |
| Radius Health, INC. | $582.77 | 2019-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $551.85 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.26 | 2019-2025 | |
| Abbott Laboratories | $421.50 | 2022-2024 | Freestyle Libre 3 |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masha Nakelchik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.